has signed a $1 million contract with a global pharmaceutical company for its DXRX platform.
The value of the contract will be spread out across five years, covering multiple products and subject to certain milestones being met. Under the deal, Diaceutics will deliver customised data insights through the platform, with a set of real-world data and insights on lab test results that identify physicians who are treating patients in their target cohorts.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: